Regel Therapeutics, a gene regulation company, has tapped Stephen J. Farr, PhD, as its Chief Executive Officer (CEO).
 
Farr served as President and CEO of Zogenix from 2015 until its acquisition by UCB in 2022. He transformed Zogenix into a leading rare disease company, highlighted by the approval of FINTEPLA in the US, Europe and Japan. Before that, Farr served as Zogenix’s President and Chief Operating Officer since its founding in 2006. Previously, Farr was Sr. Vice President and Chief Scientific Officer at Aradigm Corp. From 1986 to 1995, Farr held tenured academic positions at Cardiff University, United Kingdom, concentrating in advanced drug delivery and biopharmaceutics.
 
“We are excited to have Steve lead Regel Therapeutics and believe that his vision and experience will build a strong team focused on patient outcomes,” said Dr. Megan McGill, Regel’s interim CEO.
 
“I am thrilled to join Regel, a company that has pioneered cell-specific gene control,” said Farr. “Regel has a powerful yet elegant scientific approach to cure genetic disorders that lack disease modifying therapies. The talented and passionate team has made key scientific innovations to regulate gene expression to restore normal cellular functions. Regel’s pipeline includes proprietary programs as well as a research collaboration with Sarepta Therapeutics.”
 
Farr is on the board of directors of Mahzi Therapeutics, a preclinical company focused on developing treatments for under-served rare genetic neurodevelopmental disorders. He is also co-founder and CEO of Ataraxia Therapeutics, a seed-stage company discovering small molecule therapeutics for a novel CNS target. Previously, he was a board member at Tevard Biosciences, a preclinical company developing tRNA based therapeutics to treat rare genetic diseases and director at SteadyMed, Inc. until its acquisition by United Therapeutics.